Candel Therapeutics Inc (CADL) Stock Sees a8.13 Increase

In the past week, CADL stock has gone up by 6.83%, with a monthly gain of 96.43% and a quarterly surge of 584.59%. The volatility ratio for the week is 12.79%, and the volatility levels for the last 30 days are 13.45% for Candel Therapeutics Inc The simple moving average for the last 20 days is 49.53% for CADL’s stock, with a simple moving average of 454.82% for the last 200 days.

Is It Worth Investing in Candel Therapeutics Inc (NASDAQ: CADL) Right Now?

Moreover, the 36-month beta value for CADL is -0.75. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”

The public float for CADL is 16.66M and currently, short sellers hold a 6.33% of that float. On May 15, 2024, CADL’s average trading volume was 5.53M shares.

CADL) stock’s latest price update

Candel Therapeutics Inc (NASDAQ: CADL) has experienced a rise in its stock price by 8.13 compared to its previous closing price of 10.70. However, the company has seen a gain of 6.83% in its stock price over the last five trading days. Seeking Alpha reported 2024-04-15 that Candel Therapeutics, Inc. released positive interim results from the phase 2 study using CAN-2409 for treatment of patients with pancreatic ductal adenocarcinoma; Patients that took the drug with SOC achieved mOS of 28.8 months. Orphan Drug Designation is given by FDA for CAN-2409 for the treatment of patients with borderline respectable pancreatic ductal adenocarcinoma. Results from phase 2 study using CAN-2409 for the treatment of patients with non-small cell lung cancer, expected Q2 of 2024.

Analysts’ Opinion of CADL

Many brokerage firms have already submitted their reports for CADL stocks, with H.C. Wainwright repeating the rating for CADL by listing it as a “Buy.” The predicted price for CADL in the upcoming period, according to H.C. Wainwright is $11 based on the research report published on December 02, 2022 of the previous year 2022.

BMO Capital Markets, on the other hand, stated in their research note that they expect to see CADL reach a price target of $18. The rating they have provided for CADL stocks is “Outperform” according to the report published on November 19th, 2021.

UBS gave a rating of “Buy” to CADL, setting the target price at $9 in the report published on August 23rd of the previous year.

CADL Trading at 138.17% from the 50-Day Moving Average

After a stumble in the market that brought CADL to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 1.49% of gains for the given period.

Volatility was left at 13.45%, however, over the last 30 days, the volatility rate increased by 12.79%, as shares surge +116.54% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +622.70% upper at present.

During the last 5 trading sessions, CADL rose by +8.77%, which changed the moving average for the period of 200-days by +990.74% in comparison to the 20-day moving average, which settled at $8.05. In addition, Candel Therapeutics Inc saw 687.04% in overturn over a single year, with a tendency to cut further gains.

Stock Fundamentals for CADL

Current profitability levels for the company are sitting at:

  • -21.62 for the present operating margin
  • 0.32 for the gross margin

The net margin for Candel Therapeutics Inc stands at -20.83. The total capital return value is set at -1.4. Equity return is now at value -163.77, with -75.90 for asset returns.

Based on Candel Therapeutics Inc (CADL), the company’s capital structure generated 0.63 points at debt to capital in total, while cash flow to debt ratio is standing at -1.57. The debt to equity ratio resting at 1.71. The interest coverage ratio of the stock is -51.19.

Currently, EBITDA for the company is -37.19 million with net debt to EBITDA at 0.33. When we switch over and look at the enterprise to sales, we see a ratio of 183.49. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.00.

Conclusion

To wrap up, the performance of Candel Therapeutics Inc (CADL) has been better in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.

Most Popular

Related Posts